Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target

ABSTRACT: Purpose: We aimed to investigate the effect of several anti-leukemia drugs in combination with decitabine (DAC) on the proliferation of myeloid leukemia cells in vitro and in vivo, to select the most efficient combination group and explore associated mechanisms of these combination therapies. Experimental Design: After comparing with five anti-leukemia drugs in several different kinds of cell lines, the combination effect of idarubicin (IDA) with DAC was best. In vivo, by using microPET, TUNEL, and transmission electron microscopy, the inhibitory effects obtained by sequentially combining DAC with IDA, evidenced by evaluating tumor cell proliferation and cell apoptosis. Molecular studies were conducted using gene chip, which was used to explore associated pathways, and real-time quantita

ORGANISM(S): Homo sapiens

SUBMITTER: Kongfei Li 

PROVIDER: E-GEOD-54918 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress